BIOMAT Database Logo BIOMAT Database Logo

Natural history study of glycan accumulation in large animal models of GM2 gangliosidoses. 2020

Catlyn Cavender, and Linley Mangini, and Jeremy L Van Vleet, and Carley Corado, and Emma McCullagh, and Heather L Gray-Edwards, and Douglas R Martin, and Brett E Crawford, and Roger Lawrence
Research, BioMarin Pharmaceutical Inc., Novato, CA, United States of America.

β-hexosaminidase is an enzyme responsible for the degradation of gangliosides, glycans, and other glycoconjugates containing β-linked hexosamines that enter the lysosome. GM2 gangliosidoses, such as Tay-Sachs and Sandhoff, are lysosomal storage disorders characterized by β-hexosaminidase deficiency and subsequent lysosomal accumulation of its substrate metabolites. These two diseases result in neurodegeneration and early mortality in children. A significant difference between these two disorders is the accumulation in Sandhoff disease of soluble oligosaccharide metabolites that derive from N- and O-linked glycans. In this paper we describe our results from a longitudinal biochemical study of a feline model of Sandhoff disease and an ovine model of Tay-Sachs disease to investigate the accumulation of GM2/GA2 gangliosides, a secondary biomarker for phospholipidosis, bis-(monoacylglycero)-phosphate, and soluble glycan metabolites in both tissue and fluid samples from both animal models. While both Sandhoff cats and Tay-Sachs sheep accumulated significant amounts of GM2 and GA2 gangliosides compared to age-matched unaffected controls, the Sandhoff cats having the more severe disease, accumulated larger amounts of gangliosides compared to Tay-Sachs sheep in their occipital lobes. For monitoring glycan metabolites, we developed a quantitative LC/MS assay for one of these free glycans in order to perform longitudinal analysis. The Sandhoff cats showed significant disease-related increases in this glycan in brain and in other matrices including urine which may provide a useful clinical tool for measuring disease severity and therapeutic efficacy. Finally, we observed age-dependent increasing accumulation for a number of analytes, especially in Sandhoff cats where glycosphingolipid, phospholipid, and glycan levels showed incremental increases at later time points without signs of peaking. This large animal natural history study for Sandhoff and Tay-Sachs is the first of its kind, providing insight into disease progression at the biochemical level. This report may help in the development and testing of new therapies to treat these disorders.

UI MeSH Term Description Entries
D010743 Phospholipids Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system. Phosphatides,Phospholipid
D011134 Polysaccharides Long chain polymeric CARBOHYDRATES composed of MONOSACCHARIDES linked by glycosidic bonds. Glycan,Glycans,Polysaccharide
D002415 Cats The domestic cat, Felis catus, of the carnivore family FELIDAE, comprising over 30 different breeds. The domestic cat is descended primarily from the wild cat of Africa and extreme southwestern Asia. Though probably present in towns in Palestine as long ago as 7000 years, actual domestication occurred in Egypt about 4000 years ago. (From Walker's Mammals of the World, 6th ed, p801) Felis catus,Felis domesticus,Domestic Cats,Felis domestica,Felis sylvestris catus,Cat,Cat, Domestic,Cats, Domestic,Domestic Cat
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D020143 Gangliosidoses, GM2 A group of recessively inherited diseases characterized by the intralysosomal accumulation of G(M2) GANGLIOSIDE in the neuronal cells. Subtypes include mutations of enzymes in the BETA-N-ACETYLHEXOSAMINIDASES system or G(M2) ACTIVATOR PROTEIN leading to disruption of normal degradation of GANGLIOSIDES, a subclass of ACIDIC GLYCOSPHINGOLIPIDS. G(M2) Gangliosidoses,GM2 Gangliosidosis,Gangliosidoses GM2,GM2 Gangliosidose,GM2 Gangliosidoses,GM2, Gangliosidoses,Gangliosidose, GM2,Gangliosidosis, GM2

Related Publications

Catlyn Cavender, and Linley Mangini, and Jeremy L Van Vleet, and Carley Corado, and Emma McCullagh, and Heather L Gray-Edwards, and Douglas R Martin, and Brett E Crawford, and Roger Lawrence
Glycosphingolipid degradation and animal models of GM2-gangliosidoses.
August 1998, Journal of inherited metabolic disease,
Catlyn Cavender, and Linley Mangini, and Jeremy L Van Vleet, and Carley Corado, and Emma McCullagh, and Heather L Gray-Edwards, and Douglas R Martin, and Brett E Crawford, and Roger Lawrence
The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy.
June 2016, Pediatric endocrinology reviews : PER,
Catlyn Cavender, and Linley Mangini, and Jeremy L Van Vleet, and Carley Corado, and Emma McCullagh, and Heather L Gray-Edwards, and Douglas R Martin, and Brett E Crawford, and Roger Lawrence
Nomenclature of GM2-gangliosidoses.
May 1980, Clinical genetics,
Catlyn Cavender, and Linley Mangini, and Jeremy L Van Vleet, and Carley Corado, and Emma McCullagh, and Heather L Gray-Edwards, and Douglas R Martin, and Brett E Crawford, and Roger Lawrence
[New studies in GM2 gangliosidoses].
October 1975, Harefuah,
Catlyn Cavender, and Linley Mangini, and Jeremy L Van Vleet, and Carley Corado, and Emma McCullagh, and Heather L Gray-Edwards, and Douglas R Martin, and Brett E Crawford, and Roger Lawrence
Targeting the hexosaminidase genes: mouse models of the GM2 gangliosidoses.
January 2001, Advances in genetics,
Catlyn Cavender, and Linley Mangini, and Jeremy L Van Vleet, and Carley Corado, and Emma McCullagh, and Heather L Gray-Edwards, and Douglas R Martin, and Brett E Crawford, and Roger Lawrence
Accumulation of lysosphingolipids in tissues from patients with GM1 and GM2 gangliosidoses.
October 1992, Journal of neurochemistry,
Catlyn Cavender, and Linley Mangini, and Jeremy L Van Vleet, and Carley Corado, and Emma McCullagh, and Heather L Gray-Edwards, and Douglas R Martin, and Brett E Crawford, and Roger Lawrence
Serial 1H-MRS in GM2 gangliosidoses.
March 2008, European journal of pediatrics,
Catlyn Cavender, and Linley Mangini, and Jeremy L Van Vleet, and Carley Corado, and Emma McCullagh, and Heather L Gray-Edwards, and Douglas R Martin, and Brett E Crawford, and Roger Lawrence
Neurophysiological investigations in GM1 and GM2 gangliosidoses.
September 1984, Neuropediatrics,
Catlyn Cavender, and Linley Mangini, and Jeremy L Van Vleet, and Carley Corado, and Emma McCullagh, and Heather L Gray-Edwards, and Douglas R Martin, and Brett E Crawford, and Roger Lawrence
Thymic alterations in GM2 gangliosidoses model mice.
August 2010, PloS one,
Catlyn Cavender, and Linley Mangini, and Jeremy L Van Vleet, and Carley Corado, and Emma McCullagh, and Heather L Gray-Edwards, and Douglas R Martin, and Brett E Crawford, and Roger Lawrence
Animal model of human disease Gm2-gangliosidoses (amaurotic idiocies) types I, II, and 3.
April 1973, The American journal of pathology,
Copied contents to your clipboard!